MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Regulatory Information:
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology firm targeted on the invention and improvement of chimeric antigen receptor T cell (CAR T) therapies for most cancers, introduced the appointment of Dr. Charles Morris to the place of Chief Medical Officer. Dr. Morris will lead and supply strategic route for all medical, regulatory and medical improvement actions.
“We’re delighted to carry somebody with Dr. Morris’s huge experience and expertise on board throughout this pivotal time within the Firm,” mentioned Filippo Petti, CEO of Celyad Oncology. “Dr. Morris has performed an integral half in guiding a number of late-stage oncology medication to approval and his demonstrated observe file of management within the pharmaceutical business will vastly profit the work we’re doing at Celyad Oncology.”
Dr. Morris mentioned, “I’m comfortable to be becoming a member of Celyad Oncology throughout such a milestone wealthy yr stuffed with a number of necessary information readouts. Celyad Oncology’s distinctive allogeneic CAR T method coupled with its proprietary allogeneic applied sciences offers a wealth of fabric to create a differentiated pipeline for sufferers with unmet medical wants. I sit up for working with the crew to advance Celyad Oncology and assist make it a pacesetter within the discipline.”
Dr. Morris is a medical oncologist with over 20 years of oncology drug improvement expertise within the worldwide biotech and pharmaceutical house. Previous to becoming a member of Celyad Oncology, Dr. Morris served as Chief Medical Officer of Radius Well being and held management positions at PsiOxus Therapeutics, ImmunoGen Inc and Allos Therapeutics, the place he contributed to all phases of improvement for stable and hematological tumor indications, in addition to life-cycle administration improvement actions for FOLOTYN (pralatrexate) whereas at Allos. Earlier than serving in these positions, he was Vice President of Worldwide Medical Analysis at Cephalon, Inc., the place he helped the corporate obtain its first oncology drug approval for Treanda® (bendamustine). He spent the early years of his profession in numerous roles at AstraZeneca, the place he considerably contributed to the worldwide improvement of Faslodex (fulvestrant), co-authored a number of publications concerning fulvestrant and breast most cancers, and supported early medical improvement actions for Iressa® (gefitinib).
Dr. Morris holds a Bachelor of Medication, Bachelor of Surgical procedure and Bachelor of Medical Science in Medical Pharmacology and Therapeutics diploma from Sheffield College Medical Faculty within the UK and is a Member of the Royal Faculty of Physicians of London.
Ahead-Wanting Assertion
This launch might comprise forward-looking statements, inside the which means of relevant securities legal guidelines, together with the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements might embody statements concerning: the strategic route for the Firm’s medical, regulatory and medical improvement actions, together with upcoming information readouts. Ahead-looking statements might contain identified and unknown dangers and uncertainties which could trigger precise outcomes, monetary situation, efficiency or achievements of Celyad Oncology to vary materially from these expressed or implied by such forward-looking statements. Such threat and uncertainty contains the anticipated date of the Part 1 trial ends in the primary half of 2021, our improvement of extra shRNA-based allogenic candidates from our CYAD-200 collection in direction of medical trial, our monetary and working outcomes and the period and severity of the COVID-19 pandemic and authorities measures applied in response thereto. An additional checklist and outline of those dangers, uncertainties and different dangers will be present in Celyad Oncology’s U.S. Securities and Alternate Fee (SEC) filings and stories, together with in its Annual Report on Type 20-F filed with the SEC on March 24, 2021 and subsequent filings and stories by Celyad Oncology. These forward-looking statements converse solely as of the date of publication of this doc and Celyad Oncology’s precise outcomes might differ materially from these expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to replace any such forward-looking statements on this doc to mirror any change in its expectations with regard thereto or any change in occasions, situations or circumstances on which any such assertion is predicated, except required by legislation or regulation.